The development of CAR design for tumor CAR-T cell therapy

Dandan Xu _, Guoliang Jin, Dafei Chai, Xiaowan Zhou, Weiyu Gu, Yanyun Chong, Jingyuan Song and Junnian Zheng

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:13991-14004. https://doi.org/10.18632/oncotarget.24179

Metrics: PDF 3620 views  |   HTML 6095 views  |   ?  


Dandan Xu1,*, Guoliang Jin1,*, Dafei Chai1, Xiaowan Zhou1, Weiyu Gu1, Yanyun Chong1, Jingyuan Song1 and Junnian Zheng1,2,3

1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China

2Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China

*These authors contributed equally to this work

Correspondence to:

Jingyuan Song, email: [email protected]

Junnian Zheng, email: [email protected]

Keywords: CAR design; antigen target; co-stimulatory molecules; tumor microenvironment; safety

Received: August 30, 2017     Accepted: December 04, 2017     Published: January 12, 2018


In recent years, the chimeric antigen receptor modified T cells (Chimeric antigen receptor T cells, CAR-T) immunotherapy has developed rapidly, which has been considered the most promising therapy. Efforts to enhance the efficacy of CAR-based anti-tumor therapy have been made, such as the improvement of structures of CAR-T cells, including the development of extracellular antigen recognition receptors, intracellular co-stimulatory molecules and the combination application of CARs and synthetic small molecules. In addition, effects on the function of the CAR-T cells that the space distance between the antigen binding domains and tumor targets and the length of the spacer domains have are also being investigated. Given the fast-moving nature of this field, it is necessary to make a summary of the development of CAR-T cells. In this review, we mainly focus on the present design strategies of CAR-T cells with the hope that they can provide insights to increase the anti-tumor efficacy and safety.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24179